Related Experiment Video
Updated: Mar 23, 2026
08:49
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
16.8K
Developments in Intralesional Therapy for Metastatic Melanoma
Sarah Sloot, Omar M Rashid, Arnod A Sarnaik
1Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA. Jonathan.Zager@Moffitt.org.
Cancer Control : Journal of the Moffitt Cancer Center
|March 25, 2016
Summary
Intralesional therapy shows promise for advanced melanoma, offering good local response rates with a tolerable side effect profile. This approach may be a valuable option for select patients when tailored to individual needs.
Area of Science:
- Oncology
- Dermatology
- Immunology
Background:
- Locoregional advanced melanoma presents a significant clinical challenge requiring a multidisciplinary approach.
- Intralesional therapies have been explored for decades, yet few have advanced to phase 3 trials.
Purpose of the Study:
- To review intralesional therapies for metastatic melanoma.
- To summarize mechanisms of action, adverse events, and clinical data for selected agents.
Main Methods:
- Literature search for intralesional therapies in metastatic melanoma.
- Selection of therapies with phase 2 or higher study data for review.
Main Results:
- Intralesional therapies demonstrate encouraging outcomes in specific advanced melanoma cases.
- Optimal treatment involves individualized combinations of intralesional therapy, regional perfusion, systemic treatments, and surgery.
Conclusions:
- Intralesional therapy is a potential treatment option for select patients with unresectable, locally advanced, or metastatic melanoma.
- Favorable local response rates and a manageable adverse event profile support its consideration.
